Ascletis Pharma Inc. (ASCLETIS-B) filed its Monthly Return for the period ended 31 May 2026, indicating no changes in either authorised or issued share capital during the month.

Authorised Capital • Authorised share capital stayed at 7.00 billion ordinary shares with a par value of USD 0.0001, equivalent to total authorised capital of USD 700,000.

Issued and Treasury Shares • Issued shares remained at 1.07 billion, comprising 1.06 billion outstanding shares and 7.08 million treasury shares. • No new shares were issued and no treasury shares were transferred during May. • Repurchased shares awaiting cancellation total 5.79 million, stemming from buy-backs executed in April and October 2025 as well as December 2025.

Public Float • The company confirmed compliance with the Main Board’s 25% minimum public-float threshold as at 31 May 2026.

Share Option Schemes • 150,000 options under the 2019 Share Option Scheme were cancelled, lowering its outstanding balance to 6.36 million. • The 2025 Share Option Scheme remains unchanged at 5.47 million outstanding options. • Aggregate shares that could be issued upon exercise of in-the-money options stand at 4.05 million, while 33.09 million additional shares could be granted under the 2025 scheme.

Other Securities Instruments • The company reported no outstanding warrants, convertible securities, HDRs or other share-issuance arrangements.

Overall, Ascletis-B’s capital structure and liquidity position remained steady through May 2026, with continued adherence to Hong Kong listing requirements.